Home / Treatments / Afirma Gene Expression Classifier
Afirma Gene Expression Classifier denials: what the review data shows
Independent reviewers have decided 28 published cases where an insurer denied Afirma Gene Expression Classifier — and they overturned the insurer 92.9% of the time. A denial for Afirma Gene Expression Classifier is a starting position, not a final answer.
Published decisions
28
2001–2026
Overturned
92.9%
26 denials reversed
By condition
Published outcomes when Afirma Gene Expression Classifier was denied for these conditions.
| Condition | Decisions | Overturned |
|---|---|---|
| Thyroid Nodule | 21 | 95.2% |
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Afirma Gene Expression Classifierwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.